Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
Rhea-AI Summary
Revelation Biosciences (NASDAQ: REVB) reported financial results for the three and twelve months ended December 31, 2025, and clinical progress on its Gemini program.
Highlights: $10.7M cash at year-end, $6.7M net proceeds from January 2026 warrant inducement, positive PRIME clinical study results, and an FDA agreement on a single adaptive Phase 2/3 study for Gemini. Company expects cash runway into Q1 2027.
Positive
- Cash balance of $10.7 million at December 31, 2025
- Warrant inducement raised net proceeds of $6.7 million (Jan 2026)
- Operating cash use improved: $8.3M in 2025 vs $18.3M in 2024
- Net loss narrowed to $8.9 million in 2025 from $15.0 million
- FDA agreement on a single adaptive Phase 2/3 study for Gemini
- Positive PRIME clinical study results in late-stage CKD patients
Negative
- Cash runway limited to funding operations into Q1 2027
- Continued net loss of $8.9 million for full-year 2025
- Quarterly net loss of $2.5 million for Q4 2025
Key Figures
Market Reality Check
Peers on Argus
REVB is up 4.44% while closely scored biotech peers show mixed moves, with names like QLGN and SLXN up and ELAB and ENTO down, suggesting stock-specific drivers rather than a broad sector move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Quarterly earnings | Positive | -2.9% | Q3 2025 results with PRIME data, higher cash, and lower operating burn. |
| Aug 08 | Quarterly earnings | Neutral | -6.7% | Q2 2025 results, PRIME dosing completion, and May 2025 financing update. |
| May 08 | Quarterly earnings | Positive | +2.7% | Q1 2025 results with Gemini progress and runway through June 2025. |
| Mar 06 | Annual earnings | Negative | +0.9% | Full-year 2024 results showing higher losses and increased operating cash use. |
| Nov 08 | Quarterly earnings | Neutral | +26.8% | Q3 2024 results with declining cash, warrant proceeds, and Gemini supply progress. |
Earnings updates frequently combine Gemini progress with cash runway changes, and price reactions have been mixed, with both aligned and divergent moves versus the news tone.
Over the past five earnings cycles, Revelation has consistently tied financial updates to progress in its Gemini program. Cash has fluctuated from $6.5M at year-end 2024 to $12.7M at Q3 2025 and now $10.7M at year-end 2025, while net losses have generally trended lower. Runway guidance extended from funding into 2025, then through Q3 2026, and now into the first quarter of 2027. Today’s results continue the pattern of improved cash efficiency and Gemini advancement seen in prior releases.
Historical Comparison
In the past five earnings releases, REVB’s average move was about 4.16%. Today’s 4.44% reaction to full-year 2025 results is close to that typical earnings-day volatility.
Earnings updates have tracked Gemini’s evolution from early clinical stages to PRIME results and now an FDA-supported Phase 2/3 path, while cash runway guidance has lengthened from funding into 2025 to the first quarter of 2027.
Regulatory & Risk Context
An effective Form S-3/A filed on 2025-09-29 registers shares underlying Class I warrants. If all such warrants are exercised for cash, the company could receive up to $28,743,000, providing additional capital for development and corporate purposes without the company selling shares directly in that prospectus.
Market Pulse Summary
This announcement combines improved financial discipline with pipeline momentum. Cash rose to $10.7M at December 31, 2025, operating cash use declined to $8.3M, and annual net loss narrowed to $8.9M, supporting management’s view that runway extends into Q1 2027. At the same time, Gemini advanced with positive PRIME data and an agreed single adaptive Phase 2/3 path. Investors may watch future burn rates, additional financing tied to existing warrants, and execution on the pivotal trial design.
Key Terms
chronic kidney disease medical
acute kidney injury medical
warrant inducement financial
AI-generated analysis. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today reported its financial results for the three and twelve months ended December 31, 2025.
Corporate Highlights
Announced Positive Results from PRIME Clinical Study in late-stage chronic kidney disease patients
Announced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injury
Received net proceeds of
$6.7 million from warrant inducement in January 2026Clinical data on the potential therapeutic benefit of Gemini for the treatment of acute kidney injury (AKI) and chronic kidney disease (CKD) will be presented at the International Conference on Advances in Critical Care Nephrology in San Diego (March 29 - April 1, 2026)
"2025 was a positive year for Revelation with significant advancement of the Gemini program," said James Rolke, Chief Executive Officer of Revelation. "We look forward to building on this momentum in 2026 to expeditiously bring Gemini to patients in need and adding to shareholder value."
Results of Operations
As of December 31, 2025, Revelation had
Net cash used for operating activities for the twelve months ended December 31, 2025 was
About Gemini
Gemini is the Company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response and has been demonstrated to have the potential to treat acute and chronic diseases associated with dysregulated inflammation. Gemini is currently being evaluated as a potential treatment for acute kidney injury (GEM-AKI); Gemini is also being developed as a treatment for chronic kidney disease (GEM-CKD), as a treatment to reduce hyperinflammation and infection associated with severe burn (GEM-PBI), and as a treatment to prevent post-surgical infection (GEM-PSI). The potential of Gemini to correct dysregulated inflammation has been demonstrated in multiple preclinical models of AKI, CKD, and infection, as well as in two phase 1 clinical studies. See additional detail here.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment of chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.
For more information, please visit www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
REVELATION BIOSCIENCES, INC.
Consolidated Statements of Operations
Three Months Ended | Year Ended | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | $ | 964,189 | $ | 605,504 | $ | 4,063,857 | $ | 3,548,996 | ||||||||
General and administrative | 1,607,398 | 1,148,384 | 5,006,957 | 4,426,113 | ||||||||||||
Total operating expenses | 2,571,587 | 1,753,888 | 9,070,814 | 7,975,109 | ||||||||||||
Loss from operations | (2,571,587 | ) | (1,753,888 | ) | (9,070,814 | ) | (7,975,109 | ) | ||||||||
Other income (expense): | ||||||||||||||||
Change in fair value of warrant liability | 87 | 2,557 | 2,158 | 81,441 | ||||||||||||
Other income (expense), net | 60,493 | 25,612 | 155,007 | (7,144,868 | ) | |||||||||||
Total other income (expense), net | 60,580 | 28,169 | 157,165 | (7,063,427 | ) | |||||||||||
Net loss | $ | (2,511,007 | ) | $ | (1,725,719 | ) | $ | (8,913,649 | ) | $ | (15,038,536 | ) | ||||
Deemed dividends | - | - | (5,951,528 | ) | - | |||||||||||
Net loss attributable to common stockholders | (2,511,007 | ) | (1,725,719 | ) | (14,865,177 | ) | (15,038,536 | ) | ||||||||
Net loss per share, basic and diluted | $ | (1.65 | ) | $ | (59.76 | ) | $ | (23.95 | ) | $ | (1,052.16 | ) | ||||
Weighted-average shares used to compute net loss per share, basic and diluted | 1,524,011 | 28,876 | 620,785 | 14,293 | ||||||||||||
REVELATION BIOSCIENCES, INC.
Consolidated Balance Sheets
December 31, | December 31, | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 10,700,331 | $ | 6,499,018 | ||||
Prepaid expenses and other current assets | 111,297 | 66,699 | ||||||
Total current assets | 10,811,628 | 6,565,717 | ||||||
Property and equipment, net | 18,067 | 56,332 | ||||||
Operating lease right-of-use asset | 722,288 | - | ||||||
Other assets | 30,941 | - | ||||||
Total assets | $ | 11,582,924 | $ | 6,622,049 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 577,501 | $ | 783,621 | ||||
Accrued expenses | 1,397,644 | 1,130,046 | ||||||
Operating lease liability | 23,013 | - | ||||||
Total current liabilities | 1,998,158 | 1,913,667 | ||||||
Operating lease liability, net of current portion | 723,771 | - | ||||||
Total liabilities | 2,721,929 | 1,913,667 | ||||||
Commitments and Contingencies (Note 4) | ||||||||
Stockholders' equity: | ||||||||
Common Stock, | 1,584 | 44 | ||||||
Additional paid-in-capital | 58,278,698 | 45,213,976 | ||||||
Accumulated deficit | (49,419,287 | ) | (40,505,638 | ) | ||||
Total stockholders' equity | 8,860,995 | 4,708,382 | ||||||
Total liabilities and stockholders' equity | $ | 11,582,924 | $ | 6,622,049 | ||||
Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Revelation Biosciences (REVB) report about its cash position on February 26, 2026?
What clinical progress did REVB announce for Gemini on February 26, 2026?
How long does Revelation expect its cash to fund operations (REVB)?
How did Revelation’s operating cash use change year-over-year for 2025 (REVB)?
What were Revelation’s reported net losses for Q4 and full-year 2025 (REVB)?
What financing activity did REVB complete in January 2026 and September 2025?
